Medium impactPrior AuthMedicare Advantage
Humana: Eprontia® (topiramate) oral solution - Medicare Advantage (New, Listed Jun 24, 2026)
Effective dateJan 1, 2026
Found onJun 24, 2026
Humana · The summary is ours. The payer's notice is the final word.View original ↗
Summary
Humana Medicare Advantage has implemented a new prior authorization policy for Eprontia (topiramate) oral solution effective January 1, 2026. Prior authorization is required for all three indications: migraine prevention (age 12+), epilepsy adjunct therapy (age 2+), and epilepsy monotherapy (age 2+), with specific criteria including previous trial or intolerance to immediate-release topiramate tablets/capsules.
PolicyChanges checks Humana and other payers every day and shows what to do before a change takes effect.
See every Humana changeWhat to do
Action · 4 steps
- Before January 1, 2026: Billing team must update prior authorization systems to require approval for all Eprontia (topiramate oral solution) prescriptions for Medicare Advantage patients.Passed
- Providers must document previous trial/intolerance to immediate-release topiramate and meet age-specific criteria (12+ for migraine, 2+ for epilepsy).
- For migraine prevention, also document previous treatment/intolerance to SNRI or tricyclic antidepressants.
- Claims without prior authorization will be denied.
Related changes
See all Humana changes →Eprontia® (topiramate) oral solution (New)Published Jan 2026: Humana's Medicare Advantage policy for Eprontia (topiramate) oral solution sets prior authorization criteria for migraine prevention, epilepsy adjunct therapy,Effective Jan 1, 2026 · Medicare AdvantageMediumEprontia® (topiramate) oral solution (New)Humana Medicare Advantage now requires prior authorization for Eprontia (topiramate) oral solution effective January 1, 2026. This affects patients with epilepsy (age 2+) and…Effective Jan 1, 2026 · Medicare AdvantageMedium